Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Bacterial diadenylate cyclase domains synthesize diverse nucleotide signals in anti-phage defense.

Created on 08 Oct 2026

Authors

Adelyn E Ragucci, Danielle J Haley, Philip J Kranzusch

Published in

bioRxiv : the preprint server for biology. Aug 11, 2026. Epub Aug 11, 2026.

Abstract

Bacterial diadenylate cyclase (DAC) enzymes synthesize the nucleotide signal 3'3' cyclic di-AMP (3'3'-c-di-AMP) to control osmoregulation, cell-wall homeostasis, and DNA-damage responses. Here we discover specialized roles for DAC enzymes in bacterial immunity and define a Panoptes-like system we name Panoptoo as a DAC-containing anti-phage defense that guards against viral immune evasion. The Panoptoo protein PanS is a minimal DAC that constitutively synthesizes 3'3' cyclic UMP-AMP (3'3'-cUA) or 3'3'-c-di-AMP to negatively regulate a partnering PanE S2TMβ membrane-targeting effector. We show that Panoptoo decoy signaling acts as a counter-defense to detect phage immune evasion proteins that inhibit nucleotide immune signals. A 1.5 Å crystal structure of PanS in complex with 3'3'-cUA explains how a symmetry break in the canonical DAC active site enables synthesis of asymmetric signaling molecules. Together, our results uncover a role for DAC domains in bacterial anti-phage defense and expand our understanding of nucleotide signaling in antiviral immunity.

PMID:
42845585
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement